DeOndra Dixon INCLUDE Project Act of 2025
Summary
The DeOndra Dixon INCLUDE Project Act of 2025 (HR3491) has been introduced in the House and referred to the Committee on Energy and Commerce. This bill authorizes the NIH to establish a dedicated program for Down syndrome research, which could increase demand for genetic sequencing, diagnostic services, and pharmaceutical development. While the bill does not appropriate funds, it sets the framework for future funding opportunities.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR3491 authorizes a new NIH program for Down syndrome research, but does not appropriate funds.
- 2.The bill is in an early legislative stage, having only been introduced and referred to committee.
- 3.Companies in genetic sequencing, diagnostics, and pharmaceutical development are potential beneficiaries of future funding related to this research area.
- 4.Current market movements for related companies are not directly tied to this bill's early stage.
Market Implications
The introduction of HR3491 signals a potential future increase in research and development funding for Down syndrome, which could benefit companies involved in genetic sequencing, diagnostics, and pharmaceutical development. However, as the bill only authorizes a program and does not appropriate funds, there is no immediate direct financial impact on the market. Future appropriations bills would be required to realize the financial opportunities. Current stock performance for companies like Illumina ($ILMN) at $127.74 (7-day change: +5.74%) and Thermo Fisher Scientific ($TMO) at $488.19 (7-day change: +1.7%) reflects broader market and company-specific factors, not this early-stage legislative action.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Lowering Drug Costs for American Families Act
Most Favored Patient Act of 2026
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Ellie’s Law
Medical Research for Our Troops Act
Medicare for All Act
DLA TROOP SUPPORT: $65.0M Department of Health and Human Services Contract
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract